George Zahrah, MD
Hematology & Oncology · Norwalk, CTNPI 1871587030
Payments from drug & device makers
Across 210 payments — averaging $3073.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$605K
- Seagen Inc.$37K
- AbbVie$338
- Gilead$312
- Novartis$303
- Array Biopharma Inc$262
- plus $2K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 57 | $605,186 |
| Seagen Inc. | 9 | $37,254 |
| AbbVie | 15 | $338 |
| Gilead | 9 | $312 |
| Novartis | 12 | $303 |
| Array Biopharma Inc | 13 | $262 |
| Bristol Myers Squibb | 11 | $240 |
| AstraZeneca | 10 | $192 |
| GSK | 8 | $165 |
| Genentech USA, Inc. | 6 | $148 |
| Merck | 10 | $125 |
| Johnson & Johnson | 5 | $109 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Lilly USA, LLC | 5 | $102 |
| Clovis Oncology, Inc. | 6 | $67 |
| Eisai Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Amgen | 3 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Incyte Corporation | 2 | $35 |
| Puma Biotechnology, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $26 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 2 | $25 |
| UCB, Inc. | 1 | $25 |
| Tesaro, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Exelixis Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Legend Biotech USA Inc. | 1 | $18 |
| Sanofi | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $14 |
How this compares
$645,428 in reported general payments places this provider in the 85th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Norwalk
- Richard FrankNorwalk$3.3M
- Lisa PhuongNorwalk$216K
- Richard ZelkowitzNorwalk$87K
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Michael CecchiniNew Haven$7.8M
- Tarsheen SethiNew Haven$2.6M
- Terri ParkerNew Haven$2.4M
- Iris IsufiNew Haven$2.1M
- Jeremy KortmanskyHamden$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.